JPM 2022 Mid-Week IVD Roundup: Guardant, Illumina, Ortho Clinical, Thermo Fisher
The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies describing their experience in 2021 and expectations for 2022. Here are some highlights from the in vitro diagnostics companies that presented on the first two days of the meeting.
You may also be interested in...
Exec Chat: Illumina CMO Looks From Pandemic Boom To Future Where Genomics Is ‘Foundational’ To Health Care
Illumina’s chief medical officer Phillip Febbo discusses expanding use cases for gene sequencing, the firm’s planned introduction of new long-read sequencing technology Infinity, the status of its Grail acquisition, and additional plans for 2022.
Quidel will pay $6bn for Ortho Clinical Diagnostics. Labcorp will acquire Personal Genome Diagnostics for $575m.
Strong oncology sales have driven the company’s revenues to new heights, keeping it on target to meet its yearly revenue guidance.